Science
Biologics
Our biologics team has experience developing multiple large molecules, including monoclonal antibodies, bi-specific antibodies and fusion proteins. We use a novel, fully human phage display library and protein engineering techniques to address unique challenges of antibody development. We are currently pursuing multiple large molecules in oncology, immune and fibrotic diseases.
Kadmon is developing next-generation immuno-oncology therapeutics, specifically IL-15 containing fusion proteins, for the treatment of cancer.
IL-15 is a cytokine that expands key tumor-fighting immune cell types, including natural killer (NK), NKT cells and memory CD8+ T cells, to induce long-lasting responses. Importantly, IL-15 does not expand immunosuppressive Treg CD4 cells, allowing for a robust and durable anti-tumor response.
IL-15 has been validated in clinical trials as an immunostimulatory cytokine with potential to treat a variety of tumor types. Recombinant IL-15 has a limited therapeutic window because of its short half-life and systemic stimulation, which has limited its use at relevant doses in patients.
Kadmon’s strategy to address these challenges is to combine IL-15 with select antibodies to direct IL-15 to the tumor microenvironment. This strategy limits systemic exposure of IL-15 to potentially increase safety and tolerability.
Our lead molecule from our IL-15 fusion protein platform is KD033 (anti-PD-L1/IL-15 fusion protein), which combines an anti-PD-L1 antibody with IL-15:
KD033 demonstrates strong tumor suppressive activity and memory responses in syngeneic mouse models. We initiated a clinical trial of KD033 in Q2 2020.